Dicerna Pharmaceuticals, Inc Earning Date (DRNA)

USA |NASDAQ |USD

DRNA Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 7, 2022 Sep 2022 - - $-0.22
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 7, 2022 Sep 2022 - - $62.95M

Dicerna Pharmaceuticals, Inc's next earnings date is Monday, Nov 7, 2022 for the fiscal quarter ending Sep 2022.

DRNA Earnings Date & History Chart

DRNA Earnings & Revenue Forecast

DRNA Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $-2.00 $-3.88 $-0.41

DRNA Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-2.00 $-2.00 $-1.43

DRNA Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $191.11M $50.60M $332.20M

DRNA Earnings Date & Revenue History

DRNA Earnings History

|
Show More
Show More

DRNA Revenue History

|
Show More
Show More

Dicerna Pharmaceuticals, Inc Next Earnings Date & Report

DRNA Next Earnings Date & Report Preview: Sep 2022 (FQ)

DRNA's next earnings date is Monday, Nov 7, 2022 for the fiscal quarter ending Sep 30, 2022.

Dicerna Pharmaceuticals, Inc Previous Earnings Dates & Reports

DRNA Previous Earnings Date & Report Recap: Jun 2022 (FQ)

Dicerna Pharmaceuticals, Inc's previous earnings date was Aug 8, 2022 for its fiscal quarter ended Jun 30, 2022.

DRNA Previous Earnings Date & Report Recap: Dec 2020 (FY)

Dicerna Pharmaceuticals, Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

DRNA's earnings per share (EPS) was $-1.52, missing the consensus analysts forecast of $-1.05 by 44.76% , and higher than the previous year's EPS (Dec 2019) by -13.64%.

Revenues were $164.31M, worse than the forecast of $190.56M by -13.78%, and up by 587.36% from previous year's revenue.

The company reported a net income of $-112.75M.

Dicerna Pharmaceuticals, Inc reported a free cash flow of $163.37M for its fiscal year, compared to $-7.04M a year ago.

The company ended the fiscal year with $52.18M in total debt, an increase of 122.06% compared to the previous year.